Biotech’s pursuit of next-generation CAR-T

Resources > Immuno-Oncology > Biotech’s pursuit of next-generation CAR-T

Biotech’s pursuit of next-generation CAR-T

2021  |  Pierre-Louis Joffrin

As the industry has learnt over the past decade, cell therapy is complex and still far from perfect despite the successes. Currently, approved products are expensive, which is giving healthcare providers and insurers alike a headache, and can still cause significant side effects, most notably cytokine release syndrome and neurotoxicity. Manufacturing is also slow and not always reliable, which means some patients drop out.

Biotech has joined the pursuit of next-generation CAR-Ts and it’s not subtle. Some new, others having pivoted towards the area, there are now over 100 companies working on CAR-Ts or derivatives around the world. With the clinical successes of first-generation autologous CAR-T cell therapies, has come a diverse and frenzied field of biotech companies, all working on next-generation products to improve patient outcomes. Despite the crowd, most do seem differentiated, so what is going on and what will the clinical landscape look like when the dust settles?

View all resources
Go to Top